Table 1.

Distribution of mutations in gyrA/gyrB among 50 OFX mono‐resistant MTB isolates from patients

Patient number	Treatment history	Gender	Age	Mutations in gyrA/gyrB in isolates from patients
				gyrA	gyrB
13005	New	Male	34	D94N	WT
13137	New	Female	50	D94G	WT
13139	New	Male	60	S91P	WT
13245	New	Male	50	D94N	WT
13497	New	Female	78	S91P	WT
13523	New	Male	69	D94G	WT
13634	New	Male	57	A90V	WT
14015	New	Male	44	D94A	WT
14036	Previously treated	Male	28	D94G	WT
14044	New	Female	54	A90V	WT
14095	New	Male	33	D94N	WT
14179	Previously treated	Male	30	S91P	WT
14374	New	Female	38	D94N	WT
14399	New	Female	29	D94N	WT
14448	New	Male	31	D94A	WT
14466	New	Male	51	D94N	WT
14476	New	Male	45	A90V	WT
14603	New	Male	22	A90V	WT
14823	New	Female	57	D94A	WT
14824	New	Male	58	D94A	WT
14871	New	Male	27	D94A	WT
15043	New	Female	38	D94N	WT
15151	New	Male	82	S91P	WT
15177	New	Female	31	D94G	WT
15182	New	Male	74	A90V	WT
15196	New	Female	25	D94A	WT
15214	New	Male	67	S91P	WT
15219	New	Male	44	D94Y	WT
15426	Previously treated	Male	89	D94G	WT
15457	New	Male	56	D94Y	WT
15786	Previously treated	Male	54	D94G	WT
15369	New	Male	55	WT	T539A
15539	Previously treated	Female	81	WT	E540D
13051	New	Male	61	WT	WT
13356	New	Male	83	WT	WT
13422	New	Male	26	WT	WT
13520	Previously treated	Male	45	WT	WT
13639	New	Male	56	WT	WT
13659	New	Male	66	WT	WT
14096	New	Female	60	WT	WT
14119	New	Male	74	WT	WT
14436	New	Male	55	WT	WT
14739	New	Female	28	WT	WT
14867	New	Male	71	WT	WT
15134	Previously treated	Male	41	WT	WT
15297	New	Male	55	WT	WT
15404	New	Male	28	WT	WT
15470	Previously treated	Male	53	WT	WT
15489	New	Female	29	WT	WT
15670	New	Male	62	WT	WT

WT, wild type.